Patent ID: 8318154

Claim:
A super fast-acting insulin composition, comprising: a therapeutically effective amount of a fast-acting insulin analog for controlling blood glucose levels, wherein the fast-acting analog is insulin aspart or insulin glulisine; and an amount of a hyaluronan degrading enzyme sufficient to render the composition a super fast-acting insulin composition, wherein: the sufficient amount of a hyaluronan degrading enzyme to render the composition a super fast-acting insulin composition is 1 Unit or more hyaluronidase activity/mL; the super fast-acting insulin composition has an onset of action that is shorter than the analog alone, and a duration of action that is shorter than the analog alone, whereby, upon administration, the composition closely mimics the physiologic post-prandial insulin response of a non-diabetic subject to achieve glycemic control; and the super fast-acting insulin composition is formulated for a route of administration selected from among subcutaneous, intradermal and intraperitoneal administration.